Wendy A. Thomas

发表

An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link

Andrew I. Bell, Josef Mautner, Georg W. Bornkamm, 2009, PLoS pathogens.

Expression and function of T cell homing molecules in Hodgkin’s lymphoma

D. Adams, P. Murray, T. Ismail, 2008, Cancer Immunology, Immunotherapy.

The DNase of Gammaherpesviruses Impairs Recognition by Virus-Specific CD8+ T Cells through an Additional Host Shutoff Function

M. Ressing, M. Rowe, Jaap M Middeldorp, 2007, Journal of Virology.

CD8 T Cell Recognition of Endogenously Expressed Epstein-Barr Virus Nuclear Antigen 1

W. Hammerschmidt, A. Rickinson, N. Blake, 2004, The Journal of experimental medicine.

Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.

L. Frappier, A. Rickinson, A. Leese, 1997, Immunity.

The Epstein-Barr Virus-Encoded BILF1 Protein Modulates Immune Recognition of Endogenously Processed Antigen by Targeting Major Histocompatibility Complex Class I Molecules Trafficking on both the Exocytic and Endocytic Pathways

M. Rowe, R. Feederle, H. Delecluse, 2010, Journal of Virology.

The Epstein-Barr Virus G-Protein-Coupled Receptor Contributes to Immune Evasion by Targeting MHC Class I Molecules for Degradation

M. Ressing, A. Currin, M. Rowe, 2009, PLoS pathogens.

Different Patterns of Epstein-Barr Virus Latency in Endemic Burkitt Lymphoma (BL) Lead to Distinct Variants within the BL-Associated Gene Expression Signature

Rainer Spang, Paul Kellam, Andrew I. Bell, 2012, Journal of Virology.

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

E. Kieff, M. Rowe, A. Rickinson, 1992, The Journal of experimental medicine.

HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2

F. Khanim, L. Young, M. Rowe, 1993, Journal of virology.

Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.

A. Rickinson, J. Crocker, R. Jarrett, 2001, Cancer research.

CTL Control of EBV in Nasopharyngeal Carcinoma (NPC): EBV-Specific CTL Responses in the Blood and Tumors of NPC Patients and the Antigen-Processing Function of the Tumor Cells1

S. Leung, S. Cheung, P. Johnson, 2000, The Journal of Immunology.

Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.

A. Rickinson, R. Tierney, S. Lee, 1997, Journal of immunology.

Quantitative Studies of Epstein-Barr Virus-Encoded MicroRNAs Provide Novel Insights into Their Regulation

M. Rowe, R. Amoroso, G. Kelly, 2010, Journal of Virology.

Transporter (TAP)‐independent processing of a multiple membrane‐spanning protein, the Epstein‐Barr virus latent membrane protein 2

A. Rickinson, N. Blake, Steven P Lee, 1996, European journal of immunology.

Cyclical Expression of EBV Latent Membrane Protein 1 in EBV-Transformed B Cells Underpins Heterogeneity of Epitope Presentation and CD8+ T Cell Recognition1

M. Rowe, A. Rickinson, A. Leese, 2009, The Journal of Immunology.

Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.

P. Murray, A. Rickinson, N. Blake, 1998, Blood.